Clinical implications and guidelines for CKD in type 2 diabetes.
Rong M ZhangStephen C BainJanet B McGillEllen BurgessPublished in: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2022)
Current guidelines continue to recommend screening for CKD, blood pressure control using RAS inhibition as first line therapy, and glucose control. SGLT2 inhibition and finerenone are recent additions to current guidelines to improve CKD outcomes in T2D, based on robust clinical trial data.
Keyphrases
- chronic kidney disease
- type diabetes
- clinical trial
- blood pressure
- clinical practice
- glycemic control
- cardiovascular disease
- electronic health record
- randomized controlled trial
- insulin resistance
- study protocol
- hypertensive patients
- metabolic syndrome
- heart rate
- machine learning
- mesenchymal stem cells
- adipose tissue
- big data
- phase ii
- data analysis
- phase iii